EDGAR·FLOW

Moleculin Biotech, Inc. — Form 8-K

Filed November 16, 2026 · analyzed by the 8-K Agent
8-K ▲ Likely positive significance 72/100
What the filing says
Moleculin Biotech (market cap ~$8.8M) completed treatment of all 90 patients in Part A of its pivotal Phase 2/3 MIRACLE trial evaluating Annamycin for relapsed/refractory AML, with comprehensive data readout expected Q1 2027. The company reported Q3 2026 net loss of $6.5M (vs. $25.4M in Q3 2025), with cash position declining to $7.3M as of September 30, 2026, from $8.9M at year-end 2025. A peer-reviewed cardiac safety analysis of 90 patients across five trials showed no clinical or subclinical cardiotoxicity, and preclinical data suggest Annamycin may enhance immune response in pancreatic cancer models.
Why this rating

Trial completion is a major de-risking milestone for a $8.8M biotech; Q1 2027 data readout could validate lead asset efficacy/safety, enabling Part B and potential NDA path. Positive cardiac safety signal and additional indications are encouraging, but cash burn ($21.7M in 9 months) and low cash balance ($7.3M) pose near-term financing risk.

Tradability signal
NO TRADE

No trade: positive news with no measurable pre-read move — good news prices in within seconds and long-side continuation has shown no measured edge (this cell: -0.43% over 4 hrs, n=488). (Filing arrived outside market hours — evaluated at the next open with a live quote.)

Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.

Price action (we called it positive)
at our read · unknown
$7.59
+10 min · unknown
$7.59 ▲ 0.00%
+30 min · unknown
$7.64 ▲ 0.63%
+1 hr · unknown
$7.61 ▲ 0.24%
+4 hrs · unknown
$7.59 ▼ 0.03%

Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →

View original filing on SEC.gov ↗ MBRX · stock on Yahoo Finance ↗

See more from November 16, 2026.

EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.